Chairman & Ceo
Sentrx was a venture-backed pharmacovigilance services and IT company serving big Pharma.Michael is the co-inventor of a key Sentrx IP asset: a patent issued by the USPTO vis-à-vis an automated method for early identification of serious adverse event signals. In early 2013, Sentrx was acquired by a division of Merck & Co.